Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0091-679x(04)77001-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cooperation between SS18-SSX1 and miR-214 in Synovial Sarcoma Development and Progression.
Cancers (Basel)
January 2020
Division of Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
Article Synopsis
- SS18-SSX fusion proteins are key players in the development of synovial sarcoma, but the exact genetic mechanisms behind this process are still not fully understood.
- Researchers created a new ex vivo mouse model of synovial sarcoma using retroviral gene transfer, which consistently led to the formation of tumors that exhibit characteristics similar to human synovial sarcoma, including specific cell types and gene expressions.
- The study identified several common retroviral integration sites and indicated that specific genes, when introduced together, could accelerate the cancer’s onset, highlighting the importance of these genes in tumor development and progression.
Polycomb Repressor Complex 1 Member, BMI1 Contributes to Urothelial Tumorigenesis through p16-Independent Mechanisms.
Transl Oncol
October 2015
Leeds Institute of Cancer and Pathology, St James's University Hospital, Beckett Street, Leeds, LS97TF, UK. Electronic address:
Urothelial carcinoma (UC) causes significant morbidity and remains the most expensive cancer to treat because of the need for repeated resections and lifelong monitoring for patients with non-muscle-invasive bladder cancer (NMIBC). Novel therapeutics and stratification approaches are needed to improve the outlook for both NMIBC and muscle-invasive bladder cancer. We investigated the expression and effects of B Lymphoma Mo-MLV Insertion Region 1 (BMI1) in UC.
View Article and Find Full Text PDFMalignant transformation of mature T cells after gammaretrovirus mediated transfer of nucleophosmin-anaplastic lymphoma kinase oncogene.
Indian J Pathol Microbiol
April 2016
Pathology Department, College of Medicine, King Faisal University, AL Ahsa, Saudi Arabia.
Background: Gene therapy has been in use to cure hereditary and acquired diseases by incorporating the desired gene into the cells with the help of gammaretroviral vectors. Despite the success of this therapy in X-linked severe combined immunodeficiency syndrome, few patients developed leukemia as a major adverse event due to retroviral insertional mutagenesis within stem cells. In experimental animals also, retroviral-mediated gene transfer technique resulted in the development of leukemia.
View Article and Find Full Text PDFRetroviral-mediated Insertional Mutagenesis in Zebrafish.
Methods Cell Biol
January 2012
Koch Institute for Integrative Cancer Research, Massachusetts Institute for Technology, Cambridge, Massachusetts, USA.
Since the initial publication of this chapter in 2004, additional methodologies have been developed which could improve and/or complement the original retroviral-mediated insertional mutagenesis. Retroviral vectors have also been shown to be useful for goals other than mutagenesis. In addition, retroviral-mediated insertional mutagenesis has been applied to zebrafish for use in reverse genetics as well as forward screening.
View Article and Find Full Text PDFGenotoxicity of retroviral hematopoietic stem cell gene therapy.
Expert Opin Biol Ther
May 2011
Washington State University, Department of Pharmaceutical Sciences and School of Molecular Biosciences, P.O. Box 646534, Pullman, WA 99164-6534, USA.
Introduction: Retroviral vectors have been developed for hematopoietic stem cell (HSC) gene therapy and have successfully cured X-linked severe combined immunodeficiency (SCID-X1), adenosine deaminase deficiency (ADA-SCID), adrenoleukodystrophy, and Wiskott-Aldrich syndrome. However, in HSC gene therapy clinical trials, genotoxicity mediated by integrated vector proviruses has led to clonal expansion, and in some cases frank leukemia. Numerous studies have been performed to understand the molecular basis of vector-mediated genotoxicity with the aim of developing safer vectors and safer gene therapy protocols.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!